Dare Bioscience Inc Stock Price, News & Analysis

Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health solutions, has scheduled its Q2 2025 financial results conference call and webcast for August 14, 2025 at 4:30 p.m. ET.

Investors can join via phone at (646) 307-1963 or toll-free at (800) 715-9871 using conference ID 2684883. The webcast will be available on the company's investor relations website and archived until August 28, 2025.

Daré Bioscience (NASDAQ: DARE) and Rosy Wellness have announced the launch of a consumer awareness campaign for DARE to PLAY™ Sildenafil Cream, a groundbreaking topical formulation for women's arousal targeted for prescription availability in Q4 2025.

The campaign leverages Rosy's platform of 250,000+ women and includes an Arousal Collection and educational "Quickie" videos featuring expert Dr. Sameena Rahman. The product contains sildenafil (Viagra's active ingredient) and is clinically proven to improve genital blood flow and sexual response. This collaboration marks the first phase of a broader initiative that will include healthcare provider awareness and customer support programs.

DARE to PLAY™ will be available as a compounded drug under Section 503B of the FDCA, representing a significant advancement in women's sexual health treatment backed by clinical evidence.

Daré Bioscience (NASDAQ: DARE) announced a live webinar scheduled for August 6, 2025, to showcase DARE to PLAY™, their innovative sildenafil cream for female sexual arousal. The product, containing the same active ingredient as Viagra®, is the first and only evidence-backed sildenafil cream formulation for women, designed to improve genital blood flow and sexual response.

The webinar will feature prominent sexual health experts, including Dr. Irwin Goldstein, discussing clinical evidence and the product's proprietary formulation. DARE to PLAY™ is expected to be available by prescription in Q4 2025. The event, hosted in collaboration with The National Association of Nurse Practitioners in Women's Health, is open to clinicians, investors, and women interested in science-based sexual health solutions.

Daré Bioscience (NASDAQ: DARE) announced positive interim Phase 3 results for Ovaprene®, their investigational hormone-free monthly intravaginal contraceptive. The Data Safety Monitoring Board recommended continuing the study without modifications after reviewing safety data.

Key interim findings show a 9% pregnancy rate among treated women, aligning with pre-pivotal study expectations. While 17% of participants discontinued due to vaginal odor, no serious safety concerns were identified. The ongoing multicenter study targets 250 participants for 12-month use evaluation.

Bayer holds rights to obtain exclusive U.S. commercialization through a $20 million payment post-trial completion, with potential earnings of up to $310 million in commercial milestones plus double-digit tiered royalties.

Daré Bioscience (NASDAQ: DARE) has received a $6 million non-dilutive grant installment for developing DARE-LARC1, bringing the total received to $37.8 million of a $49 million commitment. DARE-LARC1 is a preclinical-stage long-acting reversible contraceptive utilizing their intelligent drug delivery system (DARE-IDDS) platform.

The DARE-IDDS platform, originally developed at MIT, features wireless control, precision dosing, and extended duration capabilities. The technology can deliver hundreds of individualized doses over months or years without recharging. Beyond contraception, the platform shows potential applications in obesity, diabetes, and other chronic conditions requiring precise, long-term dosing.

The company is actively exploring strategic partnerships to expand the platform's use beyond reproductive health, with $11.2 million in additional non-dilutive funding available upon achieving specific milestones.

Daré Bioscience announced the adjournment of its 2025 annual meeting of stockholders due to lack of required quorum, with fewer than a majority of shares present either in person or by proxy. The Annual Meeting will reconvene virtually on July 9, 2025, at 9:00 a.m. Pacific Time. Stockholders of record as of April 17, 2025, who haven't voted can do so online at www.proxyvote.com or by telephone at 1-800-690-6903 until July 8, 2025. Previously submitted proxies and votes remain valid unless properly revoked. The company's definitive proxy statement is available on www.proxyvote.com, the company's investor relations website, and the SEC website.

Daré Bioscience (NASDAQ: DARE) has announced a strategic partnership with Rosy Wellness to support the marketing and awareness campaign for DARE to PLAY Sildenafil Cream, a topical formulation of sildenafil citrate (Viagra's active ingredient) for female sexual arousal. The product is expected to be available by prescription in Q4 2025 as a compounded drug. Rosy Wellness, with its 250,000+ women community and endorsement from 8,000+ healthcare professionals, will leverage its digital platform to provide educational outreach and healthcare provider engagement. The collaboration aims to destigmatize female sexual health discussions, with data showing 65% of women in Rosy's community reporting arousal concerns. Daré expects to begin recording revenue in Q4 2025 through this partnership that combines Daré's clinical expertise with Rosy's digital reach and engagement model.

Daré Bioscience (NASDAQ: DARE) reported its Q1 2025 financial results and provided updates on its women's health product pipeline. The company plans to commercialize four products between 2025-2026, including Sildenafil Cream for female sexual arousal disorder, DARE-HRT1 for menopause symptoms, vaginal probiotics, and Ovaprene for contraception. Financial results show cash and equivalents of $10.3M with a working capital deficit of $9.4M. Q1 expenses decreased with R&D at $2.3M (down 31% YoY) and G&A at $2.3M. The company is pursuing a dual-path strategy, commercializing via 503B compounding while seeking FDA approvals, and plans to launch some products as branded consumer health items. A key milestone includes a data safety monitoring board interim assessment for Ovaprene's Phase 3 trial in July 2025.

Daré Bioscience (NASDAQ: DARE), a biopharmaceutical company focused on women's health, has scheduled its Q1 2025 financial results and company update conference call for May 13, 2025, at 4:30 p.m. Eastern Time. Investors can access the call via phone at (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free) using conference ID 3461324. A live webcast will be available on the company's investor relations website, with replay access until May 27, 2025.